{"analyses":[{"ciLowerLimit":"23.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"41.98","estimateComment":"95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Difference in MRD Negative Rates","paramValue":"32.87","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.91","upperLimit":"45.27","value":"38.4"},{"groupId":"OG001","lowerLimit":"64.77","upperLimit":"77.23","value":"71.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"MRD negativity was defined as having \\< 1 CLL cell per 10,000 leucocytes in peripheral blood.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"Day 1 Cycle 9 or 3 months after last IV infusion, approximately 9 months","title":"Percentage of Participants With MRD Negativity in Peripheral Blood as Measured by ASO-PCR at Completion of Combination Treatment Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}